Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil
Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...
FDA Rejects Milestone Pharmaceuticals' Etripamil Nasal Spray
The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.
Verywell Health4 天
Afrin vs. Flonase: How Do They Compare for Nasal Congestion?
Afrin and Flonase are over-the-counter nasal sprays. Learn how they compare in effectiveness, side effects, and safety to ...
Health and Me on MSN6 天
Seasonal Allergies: How To Prepare And Manage Symptoms Effectively
Seasonal allergies are more than just a nuisance—they can lead to persistent sneezing, itchy eyes, a runny nose, and a cough ...